Seelos Therapeutics (SEEL) Quarterly EPS earnings growth

Seelos Therapeutics - graphic logo of issuer SEEL

The profit potential of Seelos Therapeutics (SEEL) is embedded in the therapy of rare psychiatric pathologies and suicidal states. Quarterly EPS variability demonstrates the market's reaction to these expectations, where 0.00 represents the current metric. The business foundation relies on intranasal ketamine patents, while the primary growth driver is the preparation of Phase 2 trial results for the drug SLS-002.

Seelos Therapeutics, Inc. (SEEL) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 10/26/2024

Summary analytical data breakdowns for Seelos Therapeutics (SEEL)

- share price and consensus valuation forecast:
Comprehensive company analysis:seelostherapeutics.com - SEEL
Manufactured product of Seelos Therapeutics Inc

Seelos Therapeutics (SEEL) progress in developing the SLS-002 drug and potential partnerships with biotech firms directly impact the issuer's market capitalization. By analyzing the quarterly EPS evolution metric on the GURU.Markets platform, an investor can track net income per share dynamics, which allows for an assessment of the business's financial resilience to macroeconomic shocks and minimizes the risk of deep drawdowns during a trend reversal.

Analysis of competing companies

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|ATAI (atai.life) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research PLC (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (COMPASS Pathways PLC) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months lbpharma.us LBRX|Bright Minds Biosciences Inc (DRUG) - Earnings per share growth in annualized terms for the last twelve months|VNDA: Year-over-year net earnings per share growth for the last 12 months|Cybin Inc (CYBN) - Year-over-year net earnings per share growth for the last 12 months|Alto Neuroscience (ANRO) - Year-over-year earnings per share growth for the last twelve months|NRx Pharma - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cingulate|Year-over-year earnings per share growth for the last twelve months SILO|Year-over-year earnings per share growth for the last twelve months China Pharma (CPHI)|Quarterly EPS earnings growth Clearmind Medicine, Inc. (CMND)|Quarterly EPS earnings growth PBM (Psyence Biomedical Ltd)|SPRC (SciSparc) - Year-over-year net earnings per share trend for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth